Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 19, 2000

View Archived Issues

Cialis shows promise as ED therapy in phase II

Cangene's newest hyperimmune agent targets hepatitis C

Proinflammatory cytokines downregulated by Vasogen's immune modulation therapy

Research on Alteon's ALT-711 fueled by ADA grant; phase IIa trial on target

Genzyme acquisition of GelTex complete

SB returns to Aradigm control of phase II development of pain management system

Putative antidepressant LY-367265 exerts dual 5-HT2A receptor/5-HT transporter-antagonist effects

New company formed to develop diagnostics for prion diseases

Schering AG and Jenapharm jointly develop highly potent, selective and pure progesterone antagonist

Synsorb Biotech suspends Synsorb Pk development; Synsorb Cd moves forward

Novartis seeks FDA approval for nonsteroidal eczema therapy

Factive denied approval by FDA

NicOx advances three products into phase I clinical trials

CPMP recommends approval of Visudyne therapy for treatment of pathological myopia

Micrologix moves antiinfective agent to phase III

Data support development of Vical's gene-based cancer therapies

Phase I clinical trial on gene therapy for HIV+ children begins in L.A.

Multitargeted antifolate as salvage therapy in refractory/resistant metastatic breast cancer

Combinations of exisulind and Herceptin or Taxotere synergistic in human breast cancer cells

R-115777: an oral protein farnesyltransferase inhibitor with activity in advanced breast cancer

New retinoid-like compounds described by Allergan

Treatments for inflammatory disorders in development at Aventis inhibit cell adhesion

R&D at Texas Biotechnology leads to identification of new integrin inhibitors

Bayer's new antiviral agents particularly useful against HCMV infections

PDE7 inhibitors and their use presented by Darwin Discovery

Neurogen scientists claim new series of GABA-A receptor ligands

Antibacterial agents with quinolone-based structure designed at Japanese lab

Kaken patents new series with potential utility in inflammation, osteoporosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...